References
1. Chan YY, Jayaprakasan K, Zamora J, Thornton JG, Raine-Fenning N CA. The Prevalence of Congenital Uterine Anomalies in Unselected and High-Risk Populations: A Systematic Review - PubMed. Hum Reprod Update. 2011. p. 17(6):761-771.
2. Grimbizis GF, Gordts S, Di Spiezio Sardo A, Brucker S, De Angelis C, Gergolet M, et al. The ESHRE-ESGE consensus on the classification of female genital tract congenital anomalies. Gynecol Surg. 2013 Aug;10(3):199–212.
3. Buttram VC, Gomel V, Siegler A, DeCherney A, Gibbons W, March C. The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, Mullerian anomalies and intrauterine adhesions. Fertil Steril. 1988;49(6):944–55.
4. Bozdag G, Mumusoglu S, Zengin D, Karabulut E YB. The Prevalence and Phenotypic Features of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis - PubMed. Hum Reprod. 2016;31(12):2841‐2855. 2016. p. 31(12):2841-2855.
5. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: Population based cohort study. BMJ. 2011 Oct 22;343(7828).
6. Wang T, Fu H, Chen L, Xu Y. Pregnancy complications among women with polycystic ovary syndrome in China: A Meta-analysis. J Cent South Univ (Medical Sci. 2017 Nov 1;42(11):1300–10.
7. Palomba S, De Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575–92.
8. Hu KL, Liu FT, Xu H, Li R, Qiao J. High antimüllerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome. Fertil Steril. 2020 Feb 1;113(2):444-452.e1.
9. Hsu JY, James KE, Bormann CL, Donahoe PK, Pépin D, Sabatini ME. Müllerian-inhibiting substance/anti-Müllerian hormone as a predictor of preterm birth in polycystic ovary syndrome. J Clin Endocrinol Metab. 2018;103(11):4187–96.
10. Valdimarsdottir R, Valgeirsdottir H, Wikström AK, Kallak TK, Elenis E, Axelsson O, et al. Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Müllerian hormone levels. Reprod Biomed Online. 2019 Jul 1;39(1):141–8.
11. Taylor HS, Vanden Heuvel GB, Igarashi P. A Conserved Hox Axis in the Mouse and Human Female Reproductive System: Late Establishment and Persistent Adult Expression of the Hoxa Cluster Genes. Biol Reprod. 1997 Dec 1;57(6):1338–45.
12. Lewis EB. A gene complex controlling segmentation in Drosophila. Vol. 276, Nature. Nature; 1978. p. 565–70.
13. McGinnis W, Garber RL, Wirz J, Kuroiwa A, Gehring WJ. A homologous protein-coding sequence in drosophila homeotic genes and its conservation in other metazoans. Cell. 1984;37(2):403–8.
14. McGinnis W, Levine MS, Hafen E, Kuroiwa A, Gehring WJ. A conserved DNA sequence in homoeotic genes of the Drosophila Antennapedia and bithorax complexes. Nature. 1984;308(5958):428–33.
15. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Vol. 68, Cell. Cell; 1992. p. 283–302.
16. Mullen RD, Behringer RR. Molecular genetics of Müllerian duct formation, regression and differentiation. Sex Dev. 2014 Sep 1;8(5):281–96.
17. Krumlauf R. Hox genes in vertebrate development. Vol. 78, Cell. Cell; 1994. p. 191–201.
18. Block K, Kardana A, Igarashi P, Taylor HS. In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system. FASEB J. 2000 Jun;14(9):1101–8.
19. Massé J, Watrin T, Laurent A, Deschamps S, Guerrier D, Pellerin I. The developing female genital tract: From genetics to epigenetics. Vol. 53, International Journal of Developmental Biology. Int J Dev Biol; 2009. p. 411–24.
20. Benson G V., Lim H, Paria BC, Satokata I, Dey SK, Maas RL. Mechanisms of reduced fertility in Hoxa-10 mutant mice: Uterine homeosis and loss of maternal Hoxa-10 expression. Development. 1996;122(9):2687–96.
21. Cheng Z, Zhu Y, Su D et al. A Novel Mutation of HOXA10 in a Chinese Woman With a Mullerian Duct Anomaly - PubMed. Hum Reprod. 2011. p. 26(11):3197-3201.
22. Filippou P HR. Is Foetal Hyperexposure to Androgens a Cause of PCOS? - PubMed. Hum Reprod Update. . 2017. p. 23(4):421-432.
23. Piltonen TT, Giacobini P, Edvinsson Å, Hustad S, Lager S, Morin-Papunen L, et al. Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertil Steril. 2019 Mar 1;111(3):588-596.e1.
24. Maliqueo M, Lara HE, Sánchez F, Echiburú B, Crisosto N, Sir-Petermann T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;166(2):151–5.
25. Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016 Jan 12;7.
26. Tadaion Far F, Jahanian Sadatmahalleh S, Ziaei S, Kazemnejad A. Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers. J Ovarian Res. 2019 Nov 17;12(1).
27. Hirobe S, He WW, Lee MM, Donahoe PK. Mullerian inhibiting substance messenger ribonucleic acid expression in granulosa and sertoli cells coincides with their mitotic activity. Endocrinology. 1992;131(2):854–62.
28. Guibourdenche J, Lucidarme N, Chevenne D, Rigal O, Nicolas M, Luton D, et al. Anti-Müllerian hormone levels in serum from human foetuses and children: Pattern and clinical interest. In: Molecular and Cellular Endocrinology. Elsevier Ireland Ltd; 2003. p. 55–63.
29. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996 Feb;81(2):571–6.
30. Rajpert-De Meyts E, Jørgensen N, Græm N, Müller J, Cate RL, Skakkebæk NE. Expression of Anti-Müllerian Hormone during Normal and Pathological Gonadal Development: Association with Differentiation of Sertoli and Granulosa Cells 1 . J Clin Endocrinol Metab. 1999 Oct;84(10):3836–44.
31. Kuiri-Hänninen T, Kallio S, Seuri R, Tyrväinen E, Liakka A, Tapanainen J, et al. Postnatal developmental changes in the pituitary-ovarian axis in preterm and term infant girls. J Clin Endocrinol Metab. 2011 Nov;96(11):3432–9.
32. Hagen CP, Aksglaede L, Sørensen K, Main KM, Boas M, Cleemann L, et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–10.
33. Tata B, Mimouni NEH, Barbotin AL, Malone SA, Loyens A, Pigny P, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018 Jun 1;24(6):834–46.
34. Hart R, Sloboda DM, Doherty DA, Norman RJ, Atkinson HC, Newnham JP, et al. Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antimüllerian hormone in adolescence: A prospective cohort study. Fertil Steril. 2010 Sep;94(4):1544–7.
35. Franco HL, Dai D, Lee KY, Rubel CA, Roop D, Boerboom D, et al. WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. FASEB J. 2011 Apr;25(4):1176–87.
36. Di Spiezio Sardo A, Florio P, Nazzaro G, Spinelli M, Paladini D, Di Carlo C, et al. Hysteroscopic outpatient metroplasty to expand dysmorphic uteri (HOME-DU technique): A pilot study. Reprod Biomed Online. 2015 Feb 1;30(2):166–74.
37. Alonso L, Haimovich S, Di Spiezio Sardo A, Carugno J. Dysmorphic Uterus: Do We Need a T-Y-I Subclassification? Vol. 27, Journal of Minimally Invasive Gynecology. Elsevier B.V.; 2020. p. 4–6.